Abstract
Bladder cancer is one of the most common urothelial tumors worldwide. While there are some progresses on early bladder cancer detection, patients’ mortalities have not been changed significantly. So it is important to get further understanding the mechanism involved in the development and progression of bladder cancer. Long non-coding RNAs play important regulatory roles in a variety of biological processes ranging from gene regulation, cellular differentiation to tumorigenesis. Previous literatures reported that lncRNA ABHD11 Antisense RNA 1 (ABHD11-AS1) (Organism: Homo sapiens) was highly expressed in gastric cancer. Inspired by these observations, we hypothesized that ABHD11-AS1 possibly plays an analogous role in human bladder cancer. We first found that ABHD11-AS1 was up-regulated in bladder cancer tissues and cell lines, and ABHD11-AS1 expression level was positively associated with clinicobiological features. Cell proliferation, cell migration and apoptosis were observed by silencing ABHD11-AS1 and overexpression ABHD11-AS1 caused contrary effects. Taken together, these data suggested that ABHD11-AS1 may be an oncogene and a therapeutic target in bladder cancer.
Highlights
Malignant bladder carcinomas are the most common tumors in urinary systems
We investigated the effects of ABHD11-AS1 on cell proliferation, cell migration, and cell apoptosis in bladder cancer through inhibition or over-expression of ABHD11-AS1
Age, tumor invasion depth and lymph node metastasis had no associations with ABHD11-AS1 expression level
Summary
The diagnosis and treatment of bladder cancer has been much improved during recent years [1,2,3,4,5], there are still many questions to be solved. Long non-coding RNAs (lncRNAs) belong to a kind of non-coding RNAs which had been regarded as useless molecules in the past. They do not contain openreading frames, but have conservative secondary structures. PVT1 was reported to be highly expressed and to control cellular behaviors in bladder cancer by our group [24]. Many studies on lncRNAs were still in the primary stage, there’s a long way to transform them into application in clinical diagnosis and treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
